← Leaderboards
Douglas J Goetz
Ohio University Athens
$1,606,086
Attributed
$1,606,086
Total exposure
2
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $566.3K · FY2016–25$1M$750K$500K$250K$0
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$1,606,086 · 2
By mechanism
R15$1,606,086 · 2
Top collaborators
No co-investigators on record.
Most similar at Ohio University Athens
Same institution · by research overlap
- Vishwajeet Puri$5,641,728
- Leslie Consitt$1,148,038
- Kelly McCall$527,528
Others in their field
Top investigators on “Pathology”
- Lawrence Corey · Fred Hutchinson Cancer Center$196,976,947
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$196,976,947
- Paul S. Aisen · Cognition Therapeutics, Inc.$155,099,919
- Reisa A. Sperling · Banner Health$154,825,070
- Ronald T Mitsuyasu · University Of California Los Angeles$145,092,412
- Joseph E Robertson · Oregon Health & Science University$126,125,279
Research focus
PathologyTherapeutic DevelopmentMediatingMolecularPhosphotransferasesTherapeutic AgentsCytokineGrantGlycogen Synthase Kinase 3Metabolic DiseasesMalignant NeoplasmsHuman DiseaseScaffoldS DiseaseClinical TrialsCost EffectiveDesignDiabetes MellitusAlzheimer&AposExhibitsExpectationFoundationsHuman PathologyInnate Immune Response
Grant awards (4)
Novel Glycogen Synthase Kinase-3 (GSK-3) Inhibitors as Therapeutic Agents$566,250
R15 · FY2025 · GM · contact PI
Novel Glycogen Synthase Kinase-3 (GSK-3) Inhibitors as Therapeutic Agents$453,000
R15 · FY2021 · GM · contact PI
Novel Glycogen Synthase Kinase-3 (GSK-3) Inhibitors as Therapeutic Agents$441,836
R15 · FY2016 · GM · contact PI
Isolated PSGL-1 and Mac-1 Adhesion to Endothelium$145,000
R15 · FY2003 · GM